Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

The drugmaker has been counting on newer launches such as genetic disorder drug Skyclarys as demand falls for its once ...

Spinal muscular atrophy (SMA) treatment has evolved significantly ... onasemnogene abeparvovec-xioi (Zolgensma), nusinersen (Spinraza), and risdiplam (Evrysdi). She highlights the unique ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March ...

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer’s disease (Aduhelm), ALS (QALSODY), and several biosimilars, with active collaborations ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $54.15, a high estimate of ...

Without NIH investment, Spinraza wouldn’t have been developed ... Many of the scientists who helped develop treatments for spinal muscular atrophy, cancer and Alzheimer’s began their work ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...